As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 22, 2014
by Charles C. Chante, MD for The Philippine Star:
Disordered sleep in mid- to late life is associated with an increased risk for cognitive impairment and may alter the dynamics of the Alzheimer’s disease-associated protein amyloid-beta.
Those conclusions from three separate studies presented at the meeting drive home the clinical importance of recognizing disordered sleep as a modifiable risk factor.
Research is the first study showing that disordered sleep is a risk factor for later cognitive problems.
Colleagues studied 1,309 elderly (mean age 82 years) women who completed several days of sleep observation. Motor activity was measured via wrist actigraphy. All of the participants had several neuropsychological evaluations and cognitive measurements during the course of the 15-year longitudinal study. A subset of 298 patients also underwent polysomnography.
After 5 years, women with sleep-disordered breathing were twice as likely to develop mild cognitive impairment or dementia as were those who slept normally. There was a similar risk level for women who had delayed sleep acrophase-difficulty falling asleep before the early morning hours and trouble waking up before late morning or early afternoon, director of the memory disorders clinic at the San Francisco VA Medical Center said.
Women with nighttime wakefulness were more than twice as likely to have impaired global cognitive functioning, and twice as likely to have delayed verbal recall.
“We already know that sleep deprivation and abnormal sleep patterns are associated with falls and increased morbidity and mortality,” a professor in the department of psychiatry, neurology, epidemiology, and biostatistics at the University of California, San Francisco said. “Sleep habits are as important in prevention of dementia as diabetes and obesity.”
Brigham and Women’s Hospital Boston, found similar results in her analysis of sleep data extracted from the longitudinal Nurses Health Study. The sleep study included 15,263, who were aged 70 or older at the time of their first cognitive evaluation. These subjects were followed for 6 years with cognitive testing every other year.
The women reported their sleep duration and quality at ages 40-65 and at ages 54-79. A normal night’s seep was considered to be 7 hours.
When comparing sleep duration to later cognitive status, it was found that:
• Those who slept 5 hours per day or less had lower average cognition than those who slept 7 hours per day.
• Those who slept 9 hours per day or more also had lower average congestion than those who slept 7 hours per day.
• Too little or too much sleep was cognitive equivalent to 2 years of aging. When the researchers evaluated the effects of change in sleep duration from mid- to later life. They observed that women whose sleep changed by 2 hours per day or more had worse cognitive function than those with no change in sleep duration, independent of their initial sleep duration.“Either too little or too much sleep, and sleep duration changes over time, might contribute to cognitive decline in other results.” “This is up-and-coming research and has great implications for public health. Need to do more research in this area, especially looking at sleep and circadian rhythm strategies to target therapy.”
Also found that shortened or extended sleep patterns were entwined with abnormalities in the processing of amyloid beta peptides, which are believed to cause neuronal dysfunction in Alzheimer’s disease. Subjects with these extremes of sleep duration showed a skewed proportion of abeta-40 and Abeta-42 peptides in cerebrospinal fluid, suggesting that more amyloid could be accruing in brain plaques. Washington University, St. Louis found that the circadian pattern of Abeta secretion is altered in Alzheimer’s. Her study involved three groups: 12 Alzheimer’s patients with mean age of 72 years, 8 age-matched controls, and 10 young, healthy controls with a mean age of 36 years.
Each subject underwent hourly sampling of cerebrospinal fluid (CSF) and plasma for 36 hours during walking and sleep times. Plotted the circadian secretion patterns of abeta-40 and abeta-42, and the amyloid precursor protein (APP).
While there were no significant time-linked associations of abeta in plasma, there were differences in the CSF.
Overall, both abeta-40 and -42 CSF showed a linear increase during waking time, and dips during sleep. The age matched controls and healthy young subjects — who were presumably amyloid negative — had a steady increase in APP, Abeta-40, and Abeta-42 during waking times. But this finding was absent in subjects with Alzheimer’s.
“In this group, the abeta-40 increased much less, and the change in abeta-42 was almost absent.”
This suggests that amyloid processing is impaired in patients with the disease. Different enzymes split the APP molecule into the benign abeta-40, which is secreted into the CSF, and the toxic abeta-42 which forms brain APP cleavage, leading to retained Abeta-42.
Some studies have suggested that hypoxia alters the enzymatic cleavage of APP, allowing more abeta-42 production. This finding could have implications in people who experience years of sleep apnea, where the studies were presented.
“There is emerging evidence that hypoxia is associated with amyloidosis, but it’s too new a theory to really know,” the director of the Memory and Alzheimer’s Treatment Center at Johns Hopkins University, Baltimore, said. “The jury is still out on this relationship.”
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.